# US 2017/0283776 A1 · Reprogramming cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283776 A1
- Document ID: US20170283776A1
- Status: Published application
- Kind: A1
- Application number: 15/489,600
- Filed: 2017-04-17
- Published: 2017-10-05
- Earliest claimed: 2010-03-31
- Assignees: The Scripps Research Institute
- Applicants: The Scripps Research Institute
- Inventors: Saiyong Zhu; Sheng Ding
- Web page: https://patentgrep.com/patent/US20170283776A1

## CPC

- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2501/065: Modulators of histone acetylation
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/41: Hedgehog proteins; Cyclopamine (inhibitor)
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/73: Hydrolases (EC 3.)
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2506/094: from keratinocytes
- C12N 2506/28: from vascular endothelial cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides for methods, compositions, and kits for producing an induced pluripotent stem cell from a non-pluripotent mammalian cell using a 3′-phosphoinositide-dependent kinase-1 (PDK1) activator or a compound that promotes glycolytic metabolism as well as other small molecules.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A composition comprising an induced pluripotent stem cell (iPSC), wherein the iPSC is obtained by a method comprising:
(a) introducing into a non-pluripotent cell a polynucleotide encoding an Oct4 polypeptide;
(b) contacting the non-pluripotent cell with
(i) a small molecule selected from the group consisting of F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxalylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), and PDK1 activator (3′-phosphoinositide-dependent kinase-1), and
(ii) one or both of a TGFβ receptor/ALK5 inhibitor and a MEK inhibitor; and
(c) culturing the contacted non-pluripotent cell of (b), thereby reprogramming the non-pluripotent mammalian cell to produce an induced pluripotent stem cell;
wherein contacting the non-pluripotent cell with the small molecule enhances reprogramming when compared to without the small molecule.

### Claim 21 (depends on 20)

The composition of claim 20, wherein the PDK1 activator is:
(a) an allosteric PDK1 activator; or
(b) (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid (PS48), (Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid (PS08), 2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylthio)acetic acid, (Z)-5-(Napthalen-2-yl)-3-phenylpent-2-enoic acid (12Z), or (Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid (13Z).

### Claim 22

(canceled)

### Claim 23 (depends on 20)

The composition of claim 20, wherein the method further comprises one or more of:
(a) introducing into the non-pluripotent cell a polynucleotide encoding a Klf polypeptide; and
(b) introducing into the non-pluripotent cell a polynucleotide encoding a Sox-2 polypeptide.

### Claim 24

(canceled)

### Claim 25 (depends on 20)

The composition of claim 20, wherein the non-pluripotent cell is (a) a human cell; or (b) a somatic cell, a progenitor cell, or a fully differentiated cell.

### Claim 26

(canceled)

### Claim 27

A therapeutic composition comprising an induced pluripotent stem cell (iPSC), wherein the iPSC is obtained by a method comprising:
(a) introducing into a non-pluripotent cell a polynucleotide encoding an Oct4 polypeptide;
(b) contacting the non-pluripotent cell with
(i) a small molecule selected from the group consisting of F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxalylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), and PDK1 activator (3′-phosphoinositide-dependent kinase-1), and
(ii) one or both of a TGFβ receptor/ALK5 inhibitor and a MEK inhibitor; and
(c) culturing the contacted non-pluripotent cell of (b), thereby reprogramming the non-pluripotent mammalian cell to produce an induced pluripotent stem cell;
wherein contacting the non-pluripotent cell with the small molecule enhances reprogramming when compared to without the small molecule.

### Claim 28

A composition for use in manufacturing a pluripotent stem cell for application in regenerative medicine, wherein the composition comprises a small molecule, wherein the small molecule enhances reprogramming of a mammalian cell, and wherein the small molecule is selected from the group consisting of F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxalylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), or a PDK1 (3′-phosphoinositide-dependent kinase-1) activator.

### Claim 29 (depends on 28)

The composition of claim 28, wherein the PDK1 activator is:
(a) an allosteric PDK1 activator; or
(b) (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid (PS48), (Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid (PS08), 2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylthio)acetic acid, (Z)-5-(Napthalen-2-yl)-3-phenylpent-2-enoic acid (12Z), or (Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid (13Z).

### Claim 30 (depends on 28)

The composition of claim 28, wherein the mammalian cell is (a) a human cell; or (b) a somatic cell, a progenitor cell, a fully differentiated cell, a non-pluripotent cell, or a pluripotent cell.

### Claim 31

(canceled)

### Claim 32

A kit comprising a small molecule that enhances reprogramming when used for a method of obtaining an induced pluripotent stem cell (iPSC) comprising:
(a) introducing into a non-pluripotent cell a polynucleotide encoding an Oct4 polypeptide;
(b) contacting the non-pluripotent cell with
(i) the small molecule, wherein the small molecule enhancing reprogramming is selected from the group consisting of F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxalylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), and PDK1 activator (3′-phosphoinositide-dependent kinase-1), and
(ii) a MEK inhibitor; and
(c) culturing the contacted non-pluripotent cell of (b), thereby reprogramming the non-pluripotent mammalian cell to produce an induced pluripotent stem cell;
wherein contacting the non-pluripotent cell with the small molecule enhances reprogramming when compared to without the small molecule.

### Claim 33 (depends on 32)

The kit of claim 32, further comprising a non-pluripotent mammalian cell.

### Claim 34 (depends on 32)

The kit of claim 32, further comprising at least one exogenous transcription factor comprising Oct4, and optionally one or both of Sox2 and Klf; wherein the at least one exogenous transcription factor is a polypeptide, or a polynucleotide encoding the polypeptide.

### Claim 35 (depends on 32)

The kit of claim 32, wherein
(a) the PDK1 activator is an allosteric PDK1 activator; or
(b) the PDK1 activator is (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid (PS48), (Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid (PS08), 2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylthio) acetic acid, (Z)-5-(Napthalen-2-yl)-3-phenylpent-2-enoic acid (12Z), or (Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid (13Z); or
(c) the MEK inhibitor is PD0325901.

### Claim 36

(canceled)

### Claim 37 (depends on 32)

The kit of claim 32, further comprising one or more of a TGFβ receptor/ALK5 inhibitor, a glycogen synthase kinase 3 (GSK3) inhibitor, and a histone deacetylase (HDAC) inhibitor and wherein said method further comprises contacting the non-pluripotent cell with said one or more of a TGFβ receptor/ALK5 inhibitor, a glycogen synthase kinase 3 (GSK3) inhibitor, and a histone deacetylase (HDAC) inhibitor.

### Claim 38 (depends on 37)

The kit of claim 37, wherein
(a) the TGFβ receptor/ALK5 inhibitor is A-83-01; or
(b) the HDAC inhibitor is sodium butyrate (NaB) or valproic acid (VPA).

### Claim 39 (depends on 32)

The kit of claim 32, wherein the non-pluripotent cell is (a) a human cell; or (b) a somatic cell, a progenitor cell, or a fully differentiated cell.

### Claim 40

(canceled)

### Claim 41

A method of making a therapeutic composition comprising an induced pluripotent stem cell (iPSC) for tissue regeneration in a subject in need thereof, wherein said iPSC is obtained by a method comprising:
(a) introducing into a non-pluripotent cell a polynucleotide encoding an Oct4 polypeptide;
(b) contacting the non-pluripotent cell with
(i) a small molecule selected from the group consisting of F2,6P (fructose 2,6-bisphosphate), F6P (fructose 6-phosphate), DNP (2,4-dinitrophenol), NOG (N-oxalylglycine), QC (quercetin), 2-HA (2-hydroxyglutaric acid), NA (nicotinic acid), and PDK1 activator (3′-phosphoinositide-dependent kinase-1), and
(ii) one or both of a TGFβ receptor/ALK5 inhibitor and a MEK inhibitor; and
(c) culturing the contacted non-pluripotent cell of (b), thereby reprogramming the non-pluripotent mammalian cell to produce an induced pluripotent stem cell;
wherein contacting the non-pluripotent cell with the small molecule enhances reprogramming when compared to without the small molecule.

### Claim 42

(canceled)

### Claim 43 (depends on 41)

The method of claim 41, wherein:
(a) the PDK1 activator is an allosteric PDK1 activator; or
(b) the PDK1 activator is (Z)-5-(4-Chlorophenyl)-3-phenylpent-2-enoic acid (PS48), (Z)-5-(4-Bromo-2-fluorophenyl)-3-phenylpent-2-enoic acid (PS08), 2-(3-(4-Chlorophenyl)-3-oxo-1-phenylpropylthio) acetic acid, (Z)-5-(Napthalen-2-yl)-3-phenylpent-2-enoic acid (12Z), or (Z)-5-(1H-Indol-3-yl)-3-phenylpent-2-enoic acid (13Z); or
(c) the MEK inhibitor is PD0325901.

### Claim 44

(canceled)

### Claim 45 (depends on 41)

The method of claim 41, wherein said method further comprises contacting the non-pluripotent cell with one or more of a TGFβ receptor/ALK5 inhibitor, a glycogen synthase kinase 3 (GSK3) inhibitor, and a histone deacetylase (HDAC) inhibitor.

### Claim 46 (depends on 45)

The method of claim 45, wherein
(a) the TGFβ receptor/ALK5 inhibitor is A-83-01; or
(b) the HDAC inhibitor is sodium butyrate (NaB) or valproic acid (VPA).

### Claim 47 (depends on 41)

The method of claim 41, wherein the non-pluripotent cell is (a) a human cell; or (b) a somatic cell, a progenitor cell, or a fully differentiated cell.

### Claim 48

(canceled)
